针对HIV-1（HTLV-IIIB和HTLV-IIIRF）以及HIV-2（SBL-6669和新分离株SBL-K135）的交叉中和抗体。

Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135).

作者信息

Böttiger B, Karlsson A, Andreasson P A, Naucler A, Costa C M, Biberfeld G

机构信息

Department of Immunology, National Bacteriological Laboratory, Stockholm, Sweden.

出版信息

AIDS Res Hum Retroviruses. 1989 Oct;5(5):525-33. doi: 10.1089/aid.1989.5.525.

DOI:10.1089/aid.1989.5.525

PMID:2590556

Abstract

A total of 57 HIV-1 antibody-positive sera and 43 HIV-2 antibody-positive sera were all tested for neutralizing capacity against two HIV-1 isolates (HTLV-IIIB and HTLV-IIIRF) and two HIV-2 isolates (SBL-6669 and SBL-K135). SBL-K135 is a new HIV-2 isolate obtained from a patient with clinical AIDS from Guinea-Bissau. Among the HIV-1--positive sera, 84% neutralized any of the HIV-1 isolates, 67% neutralized both HIV-1 isolates, and 35% neutralized any of the HIV-2 isolates. Among the HIV-2--positive sera, 91% neutralized any of the HIV-2 isolates, 67% neutralized both HIV-2 isolates, and 37% neutralized any of the HIV-1 isolates. Thus, neutralizing antibodies in HIV-1-- and HIV-2--positive sera can be cross-reacting, type-specific, or strain-specific. The cross-neutralizing titers were lower than the neutralizing titers against the type-specific viral isolates. The presence of cross-neutralizing antibodies was related to the presence of neutralizing antibodies against both type-specific isolates.

摘要

总共对57份HIV-1抗体阳性血清和43份HIV-2抗体阳性血清进行了针对两种HIV-1毒株（HTLV-IIIB和HTLV-IIIRF）以及两种HIV-2毒株（SBL-6669和SBL-K135）的中和能力检测。SBL-K135是从几内亚比绍一名临床艾滋病患者身上分离得到的新型HIV-2毒株。在HIV-1阳性血清中，84%能中和任何一种HIV-1毒株，67%能中和两种HIV-1毒株，35%能中和任何一种HIV-2毒株。在HIV-2阳性血清中，91%能中和任何一种HIV-2毒株，67%能中和两种HIV-2毒株，37%能中和任何一种HIV-1毒株。因此，HIV-1和HIV-2阳性血清中的中和抗体可能是交叉反应性、型特异性或毒株特异性的。交叉中和效价比针对型特异性病毒毒株的中和效价低。交叉中和抗体的存在与针对两种型特异性毒株的中和抗体的存在有关。